2013年，公司总营业额为15.88亿欧元，其中的12%投入研发。 “研发是生物梅里埃致胜的法宝。我们有超过1000名的研发人员，使公司的产品始终保持在业界先进水平” ，柏谦立先生说。随着经济的快速发展，中国市场已经成为生物梅里埃的主要战略重点之一，除法国和美国之外，中国的研发中心正在承担越来越重要的角色。“我们希望结合中国市场特色创新技术，生产便捷、快速、廉价的产品，‘生产在中国，创新在中国’，talking strip就是这一核心理念最好的体现。”他强调。
BioMérieux: temporize, progress, and growth with the tide of the time.
Newspaper reporter: Wu Hongyue
On March 26, President Xi Jinping and his wife Peng Liyuan come to bioMérieux company’s showrooms to visit the diagnostic results of bacteriology and infectious diseases while they visited in France. For this, all staff of bioMérieux feel a great delight. Data show that bioMérieux’s market share in China has ranked the third among its global market business, and will soon climb to be the second. On June 12, Mr. Thierry Bernard, global vice president of bioMérieux, said that bioMérieux will expand its business in China, increase R&D investment, promote leading innovation in the field of IVD and food safety, and actively participate in the healthcare program by Chinese government, and implement the core objective of “In China, For China, With China", and he also said bioMérieux is always developing with China jointly, while he was interviewed by the reporter from Science and Technology Daily.
Production in China, R & D in China
A strip, whose size is same as IPHONE5, there are several small hollowed holes in it, and each represents a kind of bacteria. When you dropping the sample on the hole, the strip will immediately detect which type of bacteria are existing. This product is called “talking strip”, which is researched in China and currently in commissioning phase, will be available worldwide in the near future. And its price is only one euro” said Mr. Thierry Bernard, “the characteristics of the product is inexpensive, simple-to-use, portable, and very suitable for those primary healthcare institutions in remote areas”.
BioMérieux is the largest IVD company in France, the world's largest micro-organisms IVD company. And in the field of clinical microbiology and industrial application of microbial field, its global market share ranks the first; In infectious disease diagnostics industry, it ranks the third in the world, specializing in the diagnosis of AIDS and tuberculosis; In the immunoassay field, its leading product VIDAS is an automated immunoassay analyzer, and the amount of its setup utility ranks the second in the world's immunoassay laboratory. In the field of antibiotic susceptibility testing, bioMérieux is also in a world leading level; it is one of only a few companies which can perfect itself in the three-step molecular biology techniques (purification, amplification and detection).
In 2013, the company's total turnover amounted to 1.588 billion euros, of which 12% was invested in R&D. "R&D is the key to success of bioMérieux. We have more than 1,000 R&D personnel, who keep the company's product at the advanced level in the industry," Mr. Thierry Bernard said. With the rapid economic development, the Chinese market has become one of the main strategic focus of bioMérieux. In addition to France and the United States, Chinese R&D centers are taking on an increasingly important role. "We hope to product more convenient, rapid and cheap products combining with innovative technology of the Chinese market characteristics. “Production in China, Innovation in China”, talking stripe is the best embodies about the core philosophy." He stressed.
Attention on the market of primary healthcare institutions
Since entering into China, bioMérieux attaches a great importance to its support to enhance the healthcare in China. In 2005, bioMérieux and the Chinese Academy of Medical Sciences jointly set up a joint laboratory aiming at the identification of emerging pathogens and prevention of emerging infectious diseases; in 2006, bioMérieux and Shanghai Cancer Hospital of Fudan University jointly established a joint laboratory aiming at the discovery of tumor biomarkers and mainly for breast and colorectal cancer research; in 2008, the Ministry of Health and bioMérieux carried out HAI projects on the diagnosis of drug-resistant bacteria, involving in Beijing Union Medical College Hospital, China-Japan Friendship Hospital and other grade 3 and first-class hospitals; in 2010, bioMérieux support Xiangya School of Medicine of Central South University to establish a "training base for microbiological testing professionals ". In Tianjin, China's first demonstration laboratory for the detection of "MDR-TB" was established; in 2012, Changzhou CDC introduce bacteria rapid identification systems, bio-mass spectrometer, bacterial susceptibility analysis system, gene probe detection systems, microorganisms quantitative detection systems and other nine detection equipment and a central processing system from bioMérieux to achieve the microbiological testing automation and standardization. In 2013, bioMérieux and the First Affiliated Hospital of Xi'an Jiaotong University established "microbial demonstration laboratory", which is the first automated microbiological demonstration laboratory established in western China.
At the end of the year, bioMérieux will also establish joint laboratories in Chengdu, Wuhan and other places, to provide more solutions to those primary health care institutions in Midwest of China.
Mr. Thierry Bernard said that they have carried out an extensive research in those primary healthcare institutions in China, and learned that it is a great market demand. He said, "in the local primary healthcare institutions, microbiological assay platform can guide physicians a greater degree of rational use of antibiotics. For hospitals, the establishment of appropriate laboratory can provide more comprehensive and real-time bacterial identification and susceptibility data and share nosocomial infections information systems, and effectively improve the timeliness and responsiveness of infection detection, so as to lay a good foundation for the effective control of nosocomial infections."
Development with history and the long-term perspective
In 1978, Mr. Alain Mérieux, the president of bioMérieux, came to China for the first time to seek cooperation. That is just a time when China has just started reform and opening up. He opened up a broad space for Sino-French cooperation in health field.
Since the 1980s, bioMérieux has set up its branches in Hong Kong and Shanghai, Beijing, Guangzhou and Chengdu. After their development for 30 years, the amount of users of automated microbial identification and analysis system has reached more than 1400, automatic microbial culture system has reached more than 700 users, with more than 60 automatic bacteria counting systems, users for manual testing products has covered 70% of the provinces. Meanwhile, Fondation Mérieux has also been established to support the TB prevention and control in Xinjiang, Guangxi and other areas and also develop research and innovation talents.
In recognition of the positive contribution and devotion to Chinese healthcare development by bioMérieux, in June 2011, the Minister of Health Mr. Chen Zhu granted the highest Chinese health cooperation award -"Chinese Health Award" to Mr. Alain Mérieux.
Today, China’s health care reform is gradually deepening. Focusing on the primary health care institutions, improving public health and health care system, especially improving the skills of prevention and treatment for infectious diseases in the primary health care institutions has become one of the priorities of the national health system reform. Recognizing this developing trend of China, Mr. Thierry Bernard proposed the development guideline "west, west, then west", hoping gradually extending the demonstration laboratory base construction and training for public health workers in primary health care institutions from the coast to the west areas in China.
Mr. Thierry Bernard said that the development of foreign enterprises in China should take humility, with historical vision and long-term development as a standpoint, comply with China's policies and local rules of the market, which is the only way to successfully reach the common development goals "In China, For China, With China".
Chinese traditional culture stresses "progress by the time", "taking advantage of an opportunity for development", which means doing things and behaviors should adapt itself to conform to favorable climate, combined with favorable geographical location, and support from the people, then you can have success and achievements. And this is what a true portrayal of bioMérieux successful development in China.
bioMérieux China keep a foothold in China and develop health care
Recently, bioMérieux China held the opening ceremony of the relocation of bioMérieux Beijing Branch in Beijing Marriott Hotel. BioMérieux was established in 1963, it always devotes to develop IVD products to be used in medical field and industry. The diagnostic system of bioMérieux is composed of reagent, instrument and software, mainly designed for such four strategic fields as infectious diseases, industrial microorganism control, cardiovascular diseases, and tumor. Mr. Thierry Bernard, Global Vice-president of bioMerieux, introduced the mission of BioMérieux China “Production in China, Innovation in China, and service for public health” with its specific actions and objectives, and also shared the new development of bioMérieux in China.